ZYBERNO
Stock Report
Updated Sep 1, 2026

Citius Pharmaceuticals, Inc. (CTXR)

Healthcare • NASDAQ

$0.58

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
15.0/100
POOR BUSINESS
Citius Pharmaceuticals, Inc. (CTXR) scores 15/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-73.6%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.02x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-12.8%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Citius Pharmaceuticals, Inc. (CTXR) stock report — Zyberno Score 15/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.58
Market Cap:$15.14M

Valuation Multiples (2)

P/B Ratio:0.20x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$298.72M

Price Action & Momentum (3)

Momentum Percentile:5 / 100
% of 52-Week High:26.4%
B. Profitability Assessment

Return Metrics (5)

ROA:-42.6%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (1)

Ebitda Margin:-785.4%

Yield Metrics (2)

Earnings Yield:-$222.34
Dividend Yield:1.8%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:62.9%
Latest Earnings Filed:2026-08-14
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.84x
Quick Ratio:0.40x
Cash Ratio:0.33x

Leverage Analysis (3)

Debt To Equity Ttm:0.02x
Debt-to-Equity Ratio:0.02x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-65.02x
Times Interest Earned:-65.02

Capital Structure (4)

Working Capital:-8,317,988.00
Cash And Cash Equivalents:17,007,523.00
Long Term Debt:$590.79K
Net Debt:$283.58M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$1.97M

Profitability Breakdown (2)

$26.45M-$61.38M

Bottom Line Performance (3)

-$58.17M
Income Before Tax:-$57.98M
Ebitda Ttm:-61,381,945.00

Operating Expenses (5)

Operating Expenses:66,878,645.00
R And D Expense:5,928,692.00
Sga Expense:42,166,962.00
Income Tax Expense:$189.92K
Interest Expense:592,563.00

Expense Ratios (3)

R And D To Revenue Percentage:396.9%
Sga To Revenue Percentage:2,822.8%
Ebitda Margin:-785.4%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$142.26M
Current Assets:$43.33M
Ppe Net:0.00
Goodwill:9,346,796.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:66,346,742.00
Current Liabilities:51,649,351.00
Long Term Debt:$590.79K
Short Term Debt:$300.00M

Equity & Capital (3)

Equity:$75.91M
Retained Earnings:-$277.12M
Common Stock:250,000,000.00

Working Capital Items (3)

Accounts Receivable:686,235.00
Inventory:22,625,945.00
Accounts Payable:25,913,962.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:3,810,665.00
C. Cash Flow Analysis

Operating Activities (2)

-$34.84M$0.00

Investment Activities (1)

Investing Cash Flow:-$4.40M

Financing Activities (3)

Financing Cash Flow:$20.88M
Dividends Paid Ttm:350,241.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:20,877,925.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:1,432.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.68
-$1.68
Earnings Per Share Ttm:-$2.22

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.01

Book Value & Capital (2)

Book Value Per Share:$2.90
Cash Per Share:0.65

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:0.09x
Days Inventory Outstanding Ttm:4,197.72

Payables & Cash Cycle (2)

Days Payable Outstanding:4,807.73
Cash Conversion Cycle:-1,609.01
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-9.2%
C. Company Profile & Context

Corporate Information (6)

Symbol:CTXR
Company Name:Citius Pharmaceuticals, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:26.17M
Shares Outstanding Basic:26.17M
Shares Outstanding Diluted:26.17M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 13:45:48 UTC
Data Timestamp:2026-08-21T09:51:25.724919
Scroll to Top